HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Journal of Clinical Oncology · 10.12.2023 · 41 (35) · 5363-5375
DOI: 10.1200/jco.23.01476 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.12.2023. Verfasst von Helena A Yu und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 261-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. We assessed the efficacy and safety of HER3-DXd in patients with epidermal growth factor receptor ( EGFR)–mutated non–small-cell lung cancer (NSCLC). METHODS This phase II study (ClinicalTrials.gov identifier: NCT04619004 ) was designed to evaluate HER3-DXd in patients with advanced EGFR-mutated NSCLC previously treated with EGFR tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy (PBC). Patients received HER3-DXd 5.6 mg/kg intravenously once every 3 weeks or an uptitration regimen (3.2 → 4.8 → 6.4 mg/kg). The primary end point was confirmed objective response rate (ORR; RECIST 1.1) by blinded independent central review (BICR), with a null hypothesis of 26.4% on the basis of historical data. RESULTS Enrollment into the uptitration arm closed early on the basis of a prespecified benefit-risk assessment of data from the phase I U31402-A-U102 trial. In total, 225 patients received HER3-DXd 5.6 mg/kg once every 3 weeks. As of May 18, 2023, median study duration was 18.9 (range, 14.9-27.5) months. Confirmed ORR by BICR was 29.8% (95% CI, 23.9 to 36.2); median duration of response, 6.4 months; median progression-free survival, 5.5 months; and median overall survival, 11.9 months. The subgroup of patients with previous osimertinib and PBC had similar outcomes. Efficacy was observed across a broad range of pretreatment tumor HER3 membrane expression levels and across diverse mechanisms of EGFR TKI resistance. In patients with nonirradiated brain metastases at baseline (n = 30), the confirmed CNS ORR by BICR per CNS RECIST was 33.3% (95% CI, 17.3 to 52.8). The safety profile (National Cancer Institute Common Terminology Criteria for Adverse Events v5.0) was manageable and tolerable, consistent with previous observations. CONCLUSION After tumor progression with EGFR TKI therapy and PBC in patients with EGFR-mutated NSCLC, HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases. A phase III trial in EGFR-mutated NSCLC after progression on an EGFR TKI is ongoing (HERTHENA-Lung02; ClinicalTrials.gov identifier: NCT05338970 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
- National Cancer Center Hospital, Tokyo, Japan.
- Kindai University, Osaka, Japan.
- Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
- National Taiwan University Hospital, Taipei City, Taiwan.
- Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, Germany.
ORCID-Profile: Helena A Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis Paz-Ares, Benjamin Besse, Paolo Bironzo, Dong-Wan Kim, Melissa L Johnson, Yi-Long Wu, Thomas John, Erminia Massarelli, Jyoti Patel, Egbert Smit, Karen L Reckamp, Pang-Dian Fan, Pasi A Jänne
Förderung
- NCI NIH HHS
Zitieren
APA
Yu, H. A., Goto, Y., Hayashi, H., Felip, E., Chih-Hsin Yang, J., Reck, M., Yoh, K., Lee, S. H., Paz-Ares, L., Besse, B., Bironzo, P., Kim, D. W., Johnson, M. L., Wu, Y. L., John, T., Kao, S., Kozuki, T., Massarelli, E., Patel, J., …, & Jänne, P. A. (2023). HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of Clinical Oncology, 41(35), 5363-5375. https://doi.org/10.1200/jco.23.01476
Vancouver
Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, et al. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of Clinical Oncology. 2023;41(35):5363-5375. doi:10.1200/jco.23.01476
BibTeX
@article{Yu2023,
author = {Yu, Helena A and Goto, Yasushi and Hayashi, Hidetoshi and Felip, Enriqueta and Chih-Hsin Yang, James and Reck, Martin and Yoh, Kiyotaka and Lee, Se-Hoon and Paz-Ares, Luis and Besse, Benjamin and Bironzo, Paolo and Kim, Dong-Wan and Johnson, Melissa L and Wu, Yi-Long and John, Thomas and Kao, Steven and Kozuki, Toshiyuki and Massarelli, Erminia and Patel, Jyoti and Smit, Egbert and Reckamp, Karen L and Dong, Qian and Shrestha, Pomy and Fan, Pang-Dian and Patel, Parul and Sporchia, Andrea and Sternberg, David W and Sellami, Dalila and Jänne, Pasi A},
title = {HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {35},
pages = {5363--5375},
doi = {10.1200/jco.23.01476}
}
EUVIMED